Weight loss drugs have risen in popularity. In the past three years, the number of young people taking the drugs increased by 594.4%. A new study suggests that the drugs could profoundly impact the U.S. health care system if they become widely covered by Medicare and Medicaid.
Point phone camera here
Sen. Bernie Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, is leading an investigation into Novo Nordisk, the parent company of Ozempic and Wegovy. The investigation focuses on how the company prices its weight loss medication.
Novo Nordisk responded to the investigation in a letter, emphasizing its willingness to work with lawmakers to lower prices.
Unless they can get it covered by insurance, customers can expect to shell out a pretty penny for the medication. The sticker price for a year’s supply of Ozempic is more than $12,600. Meanwhile, Wegovy retails for almost $17,600 per year.
Zepbound and Mounjaro, weight loss drugs owned by Eli Lilly and Company, go for a little less than $14,000 per year.
If someone qualifies to have the medications covered by Medicare or Medicaid, the price burden falls on federal and state programs to cover the cost. Researchers estimate that providing Wegovy to all 19.7 million Medicare beneficiaries with obesity could cost $268 billion. If the drugs were to be given to patients who are clinically diagnosed with obesity, the cost would still exceed $135 billion.
The total would be more than what Medicare spends in an entire year on retail prescription drugs.
The Senate committee found major disparities in the price that Americans pay for the drugs compared to other countries.
According to the committee’s report, the same drugs can each be purchased in Denmark, Germany and the U.K. for less than $200.
“If the prices for these products are not substantially reduced they also have the potential to bankrupt Medicare, Medicaid, and our entire health care system,” Sanders said in a letter to Novo Nordisk. “The prices for these drugs are so high in the United States that everyone — regardless of whether they use the products — will likely be forced to bear the burden of Novo Nordisk’s profit maximizing strategy through higher insurance premiums and taxes.”
In response to the report, Novo Nordisk disclosed that it retains approximately 60% of the list price of Ozempic and Wegovy in the U.S. The rest of the total is paid to the “middlemen involved in a complex U.S. healthcare system,” according to the company. Additionally, the company highlighted its $10 billion investment into the drugs over the span of a decade, but maintain that it will work with lawmakers on pricing to tackle “systemic issues.”
Demand for the drug isn’t dwindling, with 42% of Americans classified as obese.
The drugs’ prices are pushing the issue of drug pricing into the spotlight as Congress and Novo Nordisk weigh whether or not to make them affordable.
Tags: Bernie Sanders, Denmark, Eli Lilly, Germany, Health, Ozempic, prescription drugs, U.S. Senate, United Kingdom, Weight Loss
KARAH RUCKER: WEIGHT LOSS DRUGS ARE A HOT COMMODITY.
IN THE PAST THREE YEARS – THE NUMBER OF YOUNG PEOPLE TAKING THEM HAS SHOT UP NEARLY 600 PERCENT.
THE FAD BECOMING THE LATEST MOCKERY OF THE SATIRE SHOW “SOUTH PARK.”
THEY’RE POPULAR – AND PRICY.
A NEW STUDY SHOWS THE PROFOUND IMPACT IT COULD HAVE ON THE U.S. HEALTHCARE SYSTEM IF THEY BECOME MORE WIDELY COVERED BY MEDICARE AND MEDICAID.
A SENATE COMMITTEE IS INVESTIGATING THE PARENT COMPANY OF OZEMPIC AND WEGOVY – NOVO NORDISK – FOR HOW THEY PRICE THEIR WEIGHT LOSS PILLS.
NOVO NORDISK RESPONDED – SAYING ITS WILLING TO WORK WITH LAWMAKERS TO LOWER PRICES.
UNLESS SOMEONE CAN GET THE DRUGS COVERED BY INSURANCE –
THEY’RE PAYING A PRETTY PENNY.
OZEMPIC COSTS 12,600 DOLLARS FOR A YEAR’S SUPPLY.
WEGOVY RETAILS FOR 16,200 DOLLARS PER YEAR.
MOUNJARO AND ZEPBOUND ARE A LITTLE LESS THAN 14 GRAND A YEAR. (13,900, 13,800)
IF SOMEONE DOES QUALIFY TO HAVE IT COVERED BY MEDICARE OR MEDICAID –
THEN THE BURDEN FALLS ON THE FEDERAL AND STATE PROGRAMS TO COVER THE HEFTY PRICE OF THE BOOMING WEIGHT LOSS DRUGS.
RESEARCHERS ESTIMATE THAT PROVIDING WEGOVY TO ALL 19.7 MILLION MEDICARE BENEFICIARIES WITH OBESITY WOULD COST $268 BILLION DOLLARS.
IF THE DRUG WERE JUST GIVEN TO PATIENTS CLINICALLY DIAGNOSED WITH OBESITY – IT WOULD STILL BE MORE THAN 135 BILLION DOLLARS.
THAT’S MORE THAN WHAT MEDICARE SPENDS IN AN ENTIRE YEAR ON RETAIL PRESCRIPTION DRUGS.
A RECENT REPORT BY A SENATE COMMITTEE FOUND MAJOR DISPARITIES IN THE PRICE POINT AMERICANS PAY FOR THE DRUGS COMPARED TO OTHER COUNTRIES.
AMERICANS PAY 13 HUNDRED DOLLARS A MONTH FOR WEGOVY.
THE SAME MEDICATIONS COST LESS THAN TWO HUNDRED DOLLARS A MONTH IN DENMARK, GERMANY, AND THE U-K.
SENATOR BERNIE SANDERS CHAIRS THE COMMITTEE INVESTIGATING NOVO NORDISK.
HE SAYS “if the prices for these products are not substantially reduced they also have the potential to bankrupt Medicare, Medicaid, and our entire health care system. The prices for these drugs are so high in the United States that everyone — regardless of whether they use the products — will likely be forced to bear the burden of Novo Nordisk’s profit maximizing strategy through higher insurance premiums and taxes.”
NOVO NORDISK RESPONDED TO SENATOR SANDERS BY DISCLOSING THAT IT RETAINS APPROXIMATELY 60% OF THE LIST PRICE OF OZEMPIC AND WEGOVY IN THE U.S –
AND SAYS THE REST IS PAID TO “THE MIDDLEMEN INVOLVED IN A COMPLEX U.S. HEALTHCARE SYSTEM.”
NOVO NORDISK ALSO DEFENDED ITSELF BY POINTING TO THE 10 BILLION DOLLAR INVESTMENT THEY MADE IN THE DRUGS OVER THE SPAN OF A DECADE.
BUT DO SAY THEY’LL WORK WITH LAWMAKERS ON PRICING TO TACKLE WHAT THEY CALL “SYSTEMIC ISSUES.”
IT’S A DRUG THAT’S ALL THE CRAZE.
AND WITH 42 PERCENT OF AMERICAN ADULTS CLASSIFIED ASHAVING OBESEITY –
THE DEMAND IS THERE.
THE HIGHLY SOUGHT AFTER DRUGS ARE PUSHING THE DEBATE OVER DRUG PRICES FRONT AND CENTER –
AS CONGRESS AND NOVO NORDISK NOW AGREE TO COME TO THE TABLE TO DISCUSS WHETHER TO MAKE IT MORE AFFORDABLE.
I’M KARAH RUCKER.
FOR MORE STORIES LIKE THIS –
DOWNLOAD THE STRAIGHT ARROW NEWS APP OR VISIT US AT SAN DOT COM.
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.
